Compare · IMDX vs LNTH
IMDX vs LNTH
Side-by-side comparison of Insight Molecular Diagnostics Inc. (IMDX) and Lantheus Holdings Inc. (LNTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMDX and LNTH operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- LNTH is the larger of the two at $6.91B, about 39.7x IMDX ($174.4M).
- Over the past year, IMDX is up 42.9% and LNTH is up 31.4% - IMDX leads by 11.5 points.
- IMDX has been more active in the news (8 items in the past 4 weeks vs 4 for LNTH).
- LNTH has more recent analyst coverage (17 ratings vs 0 for IMDX).
- Company
- Insight Molecular Diagnostics Inc.
- Lantheus Holdings Inc.
- Price
- $5.35-1.83%
- $106.13+2.12%
- Market cap
- $174.4M
- $6.91B
- 1M return
- -13.50%
- +10.36%
- 1Y return
- +42.86%
- +31.36%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- News (4w)
- 8
- 4
- Recent ratings
- 0
- 17
Lantheus Holdings Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM Toyama Chemical Co. Ltd.; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.
Latest IMDX
- iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry
- Director Silverman Lou was granted 26,943 shares, increasing direct ownership by 74% to 63,507 units (SEC Form 4)
- Director Last Andrew J. was granted 26,943 shares, increasing direct ownership by 68% to 66,452 units (SEC Form 4)
- Director Arno Andrew was granted 32,331 shares, increasing direct ownership by 24% to 168,885 units (SEC Form 4)
- IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation
- iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress
- SEC Form 10-Q filed by Insight Molecular Diagnostics Inc.
- Insight Molecular Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest LNTH
- Director Ber Gerard covered exercise/tax liability with 381 shares, decreasing direct ownership by 1% to 27,118 units (SEC Form 4)
- Executive Chair and CEO Heino Mary Anne covered exercise/tax liability with 1,227 shares, decreasing direct ownership by 0.38% to 321,897 units (SEC Form 4)
- Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI's Image of the Year
- SEC Form SD filed by Lantheus Holdings Inc.
- Lantheus to Present at the William Blair 46th Annual Growth Stock Conference
- Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting
- Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
- Director Mchugh Julie was granted 4,137 shares, increasing direct ownership by 16% to 30,099 units (SEC Form 4)
- Director Morrow Phuong Khanh was granted 4,137 shares, increasing direct ownership by 133% to 7,237 units (SEC Form 4)